We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
21
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1962
Active, not recruiting
2
9.5%
Completed
14
66.7%
Not yet recruiting
1
4.8%
Terminated
Unknown
Withdrawn
No approval data available
- Nigeria has launched its first clinical trial using immunotherapy for colorectal cancer, marking a historic milestone as the first such trial in sub-Saharan Africa. - The Phase II study will test PD-1 blockade therapy using tislelizumab in patients with mismatch-repair deficient colorectal cancer, a genetic mutation affecting nearly 30% of Nigerian colorectal cancer patients. - The trial represents a global collaboration between Nigerian institutions (OAU, LUTH, Medserve) and Memorial Sloan Kettering Cancer Center, offering free treatment to enrolled patients. - With less than half of Nigerian colorectal cancer patients surviving one year after diagnosis, this immunotherapy approach could transform treatment outcomes for patients with limited therapeutic options.
